CRISPR Therapeutics (NASDAQ:CRSP) Issues Earnings Results

CRISPR Therapeutics (NASDAQ:CRSP) released its quarterly earnings data on Monday. The company reported ($1.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.06), Briefing.com reports. The business had revenue of $0.52 million for the quarter, compared to the consensus estimate of $12.31 million. During the same period last year, the firm earned ($0.98) earnings per share. The business’s quarterly revenue was down 99.3% compared to the same quarter last year.

CRISPR Therapeutics Stock Down 0.7 %

NASDAQ CRSP opened at $49.33 on Wednesday. The firm has a 50 day moving average of $56.97 and a two-hundred day moving average of $63.10. CRISPR Therapeutics has a 52 week low of $37.55 and a 52 week high of $91.10. The stock has a market capitalization of $4.19 billion, a PE ratio of -18.14 and a beta of 1.70.

Insider Activity

In related news, COO Julianne Bruno sold 3,366 shares of the stock in a transaction on Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the sale, the chief operating officer now owns 6,745 shares in the company, valued at approximately $378,327.05. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 4.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on CRSP shares. Citigroup cut their price objective on shares of CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating for the company in a report on Thursday, May 23rd. Piper Sandler restated an “overweight” rating and set a $105.00 price target on shares of CRISPR Therapeutics in a research report on Monday, June 17th. Chardan Capital lowered their price target on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research report on Tuesday. Needham & Company LLC lowered their price target on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Royal Bank of Canada lowered their price target on shares of CRISPR Therapeutics from $66.00 to $60.00 and set a “sector perform” rating on the stock in a research report on Tuesday. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $73.31.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.